Remove Communication Remove HIV Treatment and Prevention Agents Remove Hospitals
article thumbnail

Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention

Pharmaceutical Technology

Gilead’s recently approved drug for HIV prevention, Yeztugo (lenacapavir), has the potential to transform the pre-exposure prophylaxis (PrEP) sector in the US, according to market analysts. Go deeper with GlobalData Reports LOA and PTSR Model - BRII-732 in Human Immunodeficiency Virus (HIV).

article thumbnail

Gilead hit with FDA clinical hold for batch of HIV trials

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV treatment candidates, though the rest of the drugmaker’s diverse pipeline remains unaffected. Gilead is considered the leading big pharma in HIV treatments. Shares in Nasdaq-listed Gilead opened 0.3%

article thumbnail

Year In Review: Top Infectious Diseases Articles From 2024

IDStewardship

Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | NEJM BALANCE RCT : Among hospitalized patients with bloodstream infection, antibiotic treatment for 7 days was non-inferior to treatment for 14 days. RANDOMIZED CONTROLLED TRIALS 1. aureus bloodstream infection.